Maitra Niranjan, Adamson Cynthia, Greer Kevin, Klewer Scott, Hoying James, Bahl Joseph J, Goldman Steven, Morkin Eugene
Department of Sarver Heart Center, University of Arizona, Tucson, AZ, USA.
J Cardiovasc Pharmacol. 2007 Nov;50(5):526-34. doi: 10.1097/FJC.0b013e318142bdf2.
We have used an oligonucleotide microarray to identify genes that are affected by congestive heart failure and those influenced by treatment with DITPA and DITPA in combination with captopril using a rat postinfarction model. The most striking result when comparing heart failure to sham operation was that all of the mitochondrial and metabolic enzymes affected were down regulated. When comparing heart failure with DITPA treatment, most of the down regulated metabolic genes were returned toward normal. When comparing heart failure with heart failure animals treated with DITPA and captopril, metabolic enzymes were no longer significantly downregulated. DITPA treatment and the combination of DITPA and captopril show that the metabolic enzymes were no longer down regulated. This represents a substantial improvement in the energy- generating capacity of the heart. These results indicate that the actions of DITPA and the combination of DITPA and captopril in heart failure can be partially explained by differences in gene activation.
我们使用寡核苷酸微阵列,通过大鼠心肌梗死后模型,来鉴定受充血性心力衰竭影响的基因,以及受二碘甲状腺原氨酸(DITPA)和DITPA联合卡托普利治疗影响的基因。将心力衰竭与假手术组相比,最显著的结果是所有受影响的线粒体和代谢酶均下调。将心力衰竭与接受DITPA治疗的组相比,大多数下调的代谢基因恢复至正常水平。将心力衰竭与接受DITPA和卡托普利治疗的心力衰竭动物相比,代谢酶不再显著下调。DITPA治疗以及DITPA与卡托普利的联合使用表明,代谢酶不再下调。这代表着心脏能量生成能力有显著改善。这些结果表明,DITPA以及DITPA与卡托普利联合在心力衰竭中的作用,部分可通过基因激活的差异来解释。